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workforces in inadequately funded programmes—such
as those for safe motherhood, child survival, tackling
malnutrition, and reducing road traffic injuries—are
drained to support better paid global initiatives.
International migration of healthcare workers further
aggravates the situation.11 12 Notably, nine of the 20
countries with the highest emigration of healthcare
workers are in sub-Saharan Africa, where the
millennium health goals are least likely to be achieved.
Evidence clearly shows that density of human
resources for health at least partly explains variations
in maternal, infant, and child mortalities.13 In line with
resolutions at the World Health Assemblies in 2004
and 2005, member states are committed to solving this
problem, but no real concrete global movement has
been initiated so far.
Thirdly, accurate information is needed to monitor
progress towards the goals. But most poor countries’
health information systems are undeveloped and can-
not provide reliable data.
The Global Alliance on Vaccine and Immunization,
the Global Fund, and the Health Metrics Network
strongly emphasise the need to strengthen systems for
health and health information, but proposals made
recently at the Global Fund have not yet yielded much
success. Of the 30 proposals for strengthening health
service infrastructure, only three were approved,
because of the poor quality of the proposals. In
addition to strengthening health systems, reducing
geographical, sociocultural, and financial barriers to
care (such as user fees for services) remains just as
important.
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Trauma care research and the war on uncertainty
Improving trauma care demands large trials—and large trials need funding and
collaboration
For people aged 5-45 years trauma is second onlyto HIV/AIDS as a cause of death.1 2 Every dayworld wide over 300 000 people are severely
injured, about 10 000 of whom die. Road traffic crashes
and violence are the leading causes. The global
number of road deaths is forecast to rise by 65%
between 2000 and 2020 and the number of violent
deaths has increased steadily, with the 20th century
being the most violent on record. Despite the best pre-
ventive efforts, providing effective trauma care will
remain a major challenge for healthcare professionals.
There is considerable potential to improve trauma out-
comes by using clinical audit to increase the
implementation of evidence based interventions in
trauma services.3 However, for many trauma care inter-
ventions, the balance of risks and benefits is uncertain
and they must be assessed in randomised trials before
being implemented.
Compared with the disease burden there is a
dearth of clinical trials in trauma care and the existing
trials are small, contributing to uncertainty about effec-
tiveness (see table).4 For example, few if any of the
pharmacological treatments for brain and spinal cord
injury have ever been proved to be effective.5 To avoid
random errors, trials must recruit sufficient numbers of
patients, implying the need for large international col-
laborative trials. The CRASH trial, run by the UK’s
Medical Research Council, was designed to confirm or
refute the modest but promising effects of corticoster-
oids on outcome after traumatic brain injury by
recruiting 20 000 patients. The trial was stopped after
10 000 patients had been recruited from 239 hospitals
in 49 countries. The effect of corticosteroids was a
highly significant relative increase of 18% in all cause
mortality.6 It has been estimated that 10 000 patients
with head injuries may have died because of the inap-
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propriate administration of corticosteroids over the
past 30 years.7
Large international trials, such as the CRASH trial,
also have advantages when it comes to disseminating
results. Small trials can remain unpublished, contribut-
ing to publication bias. This is less likely with large
trials.8 In international trials collaborators around the
world have an investment in the results and
disseminate them locally. Press releases sent by the
national coordinators ensured that the results of the
CRASH trial were reported in newspapers in over 20
countries. Also, participating hospitals are more likely
to implement the results.9
There are several obstacles to conducting large
trauma trials, some relating to the subject—trauma—
and some common to all large trials. Funding for
trauma research is less than for almost any other cause
of human suffering. A WHO study compared the level
of research funding with current and projected (2020)
disease burdens.10 The results showed clearly the
relative underfunding of research on road traffic
injuries.
Doctors in many countries would collaborate in
international trauma trials but there are no well estab-
lished ways for bringing clinical trials to their attention.
Investigators try to get editorials about trials published
and will present trial protocols at conferences, but
some journals are reluctant to advertise trials or are
unwilling to publish editorials when the authors have a
stake in the trial they are writing about, which they
necessarily do.
People conducting large trials must now negotiate
a large number of regulatory, ethical, and logistic hur-
dles, not least the good clinical practice (GCP) require-
ments, which are geared towards the development of
drugs.11 Without a secure evidence base for doing so,
the demands of the good clinical practice procedures
are being indiscriminately applied not just to the drug
industry trials they were designed for but to clinical
trials of all types of interventions and to independent
investigator-led non-commercially funded studies as
well.
For example, the GCP emphasis on the monitor-
ing and auditing of trial data might not be the best use
of the scarce resources for large trials, as well as
generating thousands of miles of unnecessary travel,
when statistical approaches to monitoring may be
more effective and more appropriate. Trauma care
trials also have special circumstances and few
countries have legislation in place to handle them.
These trials take place in emergency situations,
require quick decisions for early interventions, and
include patients who are unable to give informed con-
sent (and who usually are not accompanied by anyone
who can make decisions for them). Few countries have
legislation in place for the special circumstances in
such trauma trials, and, as a result, trauma patients are
unfairly denied the benefits of medical research. Serv-
icing the numerous ethics committees involved in a
large multicentre trial also has huge resource implica-
tions and can involve long delays. The CRASH trial
collaborators completed over 500 ethics application
forms.
University promotion is often related to the
number of publications on which the researcher is first
author. This encourages competition rather than
collaboration. Collaborative trials often cite the
collaborative group rather than individuals. Some
journals accept this model but problems still arise in
indexing.12 Citing as authors only a writing group is not
a fair way of apportioning responsibility or credit.
Reward systems favour small trials with named authors
even though this increases the risk of inappropriate
inferences due to the play of chance and publication
bias.
There is an urgent need to improve the evidence
base for trauma care. Large trials can provide
important answers, but to wage war on uncertainty we
need large collaborations of equals rather than small
groups of individualists. Doctors internationally can
join these collaborations but we need ways to bring
trials to their attention, to reduce the regulatory
burden, and to reward collaboration.Most importantly,
the mismatch between the funding for trauma research
and the burden of injury must be addressed.
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Disease burden and evidence from controlled trials for main categories of human disease in sub-Saharan Africa
Disease category
Burden of disease in
2000 (1000 disability
adjusted life years)
No of
trials No of participants
Ratio of burden of disease
(1000 disability adjusted life
years)
Per trial Per participant
Malignant neoplasms 8114 46 128 786 176 0.06
Nutritional deficiencies 8389 105 111 922 80 0.07
Infectious diseases 131 327 540 813 305 243 0.16
Conditions arising during perinatal period 18 700 30 28 381 623 0.66
Cardiovascular diseases 13 390 99 5648 135 2.37
Respiratory diseases 9037 33 3320 274 2.72
Congenital anomalies 5224 2 1321 2612 3.95
Neuropsychiatric conditions 15 788 41 3580 385 4.41
Injuries 58 352 31 2887 1882 20.21
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Persistent high stroke mortality in Bangladeshi
populations
Novel hypotheses to explain this need testing urgently
Censuses in 1981, 1991,
1–3 and 2001 (Wild et al.
Persistence of substantial inequalities in car-
diovascular disease mortality by country of
birth in England and Wales 2001-2003. Unpublished
manuscript). have shown that, among Bangladeshi-
born men living in the United Kingdom, the standard-
ised mortality ratio for stroke is two to three times the
population average, with less marked but important
excesses in Bangladeshi-born women. There has been
little progress in understanding the reasons for this
variation, let alone in identifying approaches to
improve outcomes. Lessons learnt about stroke among
British Bangladeshis may well apply to other
populations at high risk, including Indians and Pakista-
nis, whose excess stroke mortality is not quite so high.
In addition, such evidence could be highly relevant to
reducing health inequalities.
Is the excess mortality from stroke in Bangladeshis
explained by a higher case fatality ratio? Interim analy-
sis of data from the south London stroke register
shows no age adjusted difference in survival between
Bangladeshis and white Europeans (albeit based on a
small population), but does find an almost doubled age
adjusted incidence of stroke in Bangladeshis (Smeeton
N, personal communication of unpublished data from
Stewart et al4). Thus, these mortality data seem to
reflect a real excess that cannot be explained by a
higher case fatality.
To what extent, then, can these differences be
explained by an excess of risk factors for stroke?
Hypertension is the most important potential
explanation, but studies conducted in east London
and Newcastle found Bangladeshi adults to have on
average a mean systolic blood pressure that is 10 mm
Hg lower than that of white Europeans.5 6 These
regional findings have been confirmed by national
data from the Health Survey for England 1999 and a
recent systematic review.7 8 Total and low density
lipoprotein cholesterol concentrations are also com-
paratively low among Bangladeshis.5 6 Bangladeshi
men tend, however, to have a high prevalence of
diabetes, smoking, physical inactivity, and high serum
triglyceride concentrations, and low serum high
density lipoprotein cholesterol concentrations.2 5–7
For women, the burden from these risk factors is
also high, except for smoking, which is uncommon.2 6
Bangladeshis are also among the poorest of Britain’s
populations.
The Framingham stroke model and European
SCORE model both predict comparatively low rates
of stroke and cerebrovascular disease. For example, in
Bangladeshi men the Framingham model predicts the
incidence of stroke to be 52% (95% confidence inter-
val 35% to 77%) of that for the white European popu-
lation.3 We need to look beyond classic stroke risk
factors.
We suggest four specific lines of investigation that
warrant consideration—squatting and straining at
stool, vitamin D deficiency, infection, and the
combined impact of smoking and tobacco chewing.
Chakrabarti’s work on three groups—patients with
stroke, healthy volunteers, and hypertensive patients—
has identified squatting as a potential causal or
precipitating factor for stroke.9 Squatting is a fairly
common posture among South Asians and is known
to raise blood pressure by about 4-8 mm Hg with a
sustained effect during the period of squatting; impor-
tantly, this blood pressure rise is greatest in the central
vasculature.
Vitamin D deficiency is very common among
Bangladeshis in London, because of a diet lacking fish,
ghee, and eggs among both sexes and lack of exposure
to sunlight, particularly among women.10 Vitamin D
deficiency may raise the risk of stroke by increasing
insulin resistance and hypertension, or may worsen
outcomes after stroke by impairing neuroprotective
mechanisms.
Chronic inflammation is a well recognised risk
factor for stroke. A recent large case series reported
that the incidences of both myocardial infarction and
stroke were significantly raised in the few days after
acute infection, particularly of the respiratory tract.11
Many Bangladeshis in the UK live in overcrowded
households, with consequent increased risk of respira-
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